Geldanamycin and its derivatives inhibit the growth of myeloma cells and reduce the expression of the MET receptor

Journal of Cancer

Volumn 5, Issue 6, 2014, Pages 480-490

  Jurczyszyn, Artur ^a   Zebzda, Anna ^a   Czepiel, Jacek ^a   Perucki, William ^a   Bazan Socha, Stanisława ^a   Cibor, Dorota ^a   Owczarek, Danuta ^a   Majka, Marcin ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

17AEP GA; 17DMAG; 17DMAP GA; Geldanamycin; Multiple myeloma

Indexed keywords

CASPASE 3; CELL SURFACE PROTEIN; GELDANAMYCIN; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CD138+ T LYMPHOCYTE; CELL CYCLE ASSAY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL COMPOSITION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; RNA ISOLATION; T LYMPHOCYTE; TUMOR INVASION; U266 CELL LINE;

EID: 84902484066     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8731     Document Type: Article

References (37)

1. Rajkumar CV. Treatment of myeloma cure vs control. Mayo Clin Proc. 2008; 83: 1142-1145.
2. Gahrton G. New therapeutic targets in multiple myeloma. Lancet. 2004; 364: 1648-1649.
3. Turner JG, Dawson J, Emmons MF, et al. CRM1 inhibition sensitizes drug resistant human myeloma cells to topoisomerase II and proteasome inhibitors both in vitro and ex vivo. J Canc. 2013; 4: 614-625.
4. Goetz MP, Toft DO, Ames MM, et al. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol. 2003; 14: 1169-1176.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70.
6. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene. 2004; 23: 2907-2918.
7. Hermisson M, Strik H, Rieger J, et al. Expression and functional activity of heat shock proteins in human glioblastoma multiforme. Neurology. 2000; 54: 1357-1365.
8. Yano M, Naito Z, Yokoyama M, et al. Expression of hsp90 and cyclin D1 in human breast cancer. Cancer Lett. 1999; 137: 45-51.
9. Lesko E, Gozdzik J, Kijowski J, et al. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo. Anticancer Drugs. 2007; 18: 1173-1181.
10. Whitesell L, Mimnaugh EG, De Costa B, et al. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins:essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 1994; 91: 8324-8328.
11. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med. 2002; 8: S55-61.
12. Powers MV, Workman P. Targeting of multiple signaling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer. 2006; 13: S125-135.
13. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 1976; 4: 267-274.
14. Bedin M, Gaben AM, Saucier C, et al. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. Int J Cancer. 2004; 109: 643-652.
15. Blagosklonny MV. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia. 2002; 16: 455-462.
16. Kim S, Kang J, Hu W, et al. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int J Cancer. 2003; 103: 352-359.
17. Sanderson S, Valenti M, Gowan S, et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther. 2006; 5: 522-532.
18. Webb CP, Hose CD, Koochekpour S, et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 2000; 60: 342-349.
19. Lee CS, Kim YJ, Lee SA, et al. Combined effect of Hsp90 inhibitor Geldanamycin and Parthenolide via Reactive Oxygen Species-mediated apoptotic process on epithelial ovarian cancer cells. Basic Clin Pharmacol Toxicol. 2012; 111: 173-181.
20. Wu MS, Lien GS, Shen SC, et al. HSP90 inhibitors, Geldanamycin and Radicicol, enhance Fisetin-induced cytotoxicity via induction of apoptosis in human colonic cancer cells. Evid Based Complement Alternat Med. 2013;:987612. doi: 10.1155/2013/987612.
21. Hartmann F, Horak EM, Cho C, et al. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines. Int J Cancer. 1997; 70: 221-229.
22. Jones DT, Addison E, North JM, et al. Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. Blood. 2004; 103: 1855-1861.
23. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002; 8: 620-627.
24. Yang J, Yang JM, Iannone M, et al. Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer Res. 2001; 61: 4010-4016.
25. Maloney A, Clarke PA, Workman P. Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr Cancer Drug Targets. 2003; 3: 331-341.
26. Nimmanapalli R, O'Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino- 17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001; 61: 1799-1804.
27. Dai C, Whitesell L. HSP90: a rising star on the horizon of anticancer targets. Future Oncol. 2005; 1: 529-540.
28. Bagatell R, Beliakoff J, David CL, et al. Hsp90 inhibitors deplete key anti- apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer. 2005; 113: 179-188.
29. Cheng JQ, Lindsley CW, Cheng GZ, et al. The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene. 2005; 24: 7482-7492.
30. Kefford R, Millward M, Hersey P. Phase 2 Trial of Tanespimycin (KOS-953), a Heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma. J Clin Oncol. ASCO. 2007; 25: 8558.
31. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3: 347-361.
32. Srethapakdi M, Liu F, Tavorath R, et al. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. 2000; 60: 3940-3946.
33. Supko JG, Hickman RL, Grever MR, et al. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995; 36: 305-315.
34. Tian ZQ, Liu Y, Zhang D, et al. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem. 2004; 12: 5317-5329.
35. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998; 42: 273-279.
36. Smith DF, Whitesell L, Nair SC, et al. Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol. 1995; 15: 6804-6812.
37. Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anti-cancer activities. Cancer Letters. 2010; 290: 24-23.